In vitro blood-brain barrier models for the study of brain shuttle peptide transport.
Getting peptides across the blood-brain barrier (BBB) has always been a major headache for researchers. Those tight junctions and selective transport systems exist to keep the brain safe, but they also block most research compounds, including promising peptides. That’s where brain shuttle peptides come in. These engineered sequences hitch a ride on the brain’s natural transport systems, acting as molecular couriers to deliver payloads where normal compounds can’t reach.
Adv Pharmacol
by Martins A, Santa-Maria AR, Kucsápszky N et al.
“In vitro blood-brain barrier models for the study of brain shuttle peptide transport. Martins A(1), Santa-Maria AR(2), Kucsápszky N(3), Santa Brígida de Barros Góes L(4), Molnár K(5), Sousa Gomes Fortes S(4), Carrilho E(6), Deli MA(1), Walter FR(7). Author information: (1)Institute of Biophysics, HUN-REN Biological Research Centre, Szeged, Hungary. (2)Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, United States. (3)Institute of Biophysics, HUN-REN Biological Research Centre, Szeged, Hungary; Doctoral School of Biology, University of Szeged, Szeged, Hungary. (4)Institute of Biophysics, HUN-REN Biological Research Centre, Szeged, Hungary; Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil. (5)Department of Neurology, Albert Szent-Györgyi Health Centre, University of Szeged, Szeged, Hungary. (6)Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil; Instituto Nacional de Ciência e Tecnologia de Bioanalítica - Lauro Kubota - INCTBio-LK, Campinas, SP, Brazil. (7)Institute of Biophysics, HUN-REN Biological Research Centre, Szeged, Hungary. Electronic address: walter.fruzsina@brc.hu. Brain shuttles, such as antibody fragments, bispecific antibodies, peptides, or nanocarriers, are engineered to exploit the blood-brain barrier (BBB) transport mechanisms to deliver therapeutics to the brain. This strategy has emerged as a potential game-changer to overcome the therapeutic challenge of many brain diseases: the hindered passage of molecules across the BBB. Due to special tight junctions, low intracellular vesicles, negatively charged glycocalyx, and highly regulated transport, brain endothelial cells limit central nervous system drug delivery. To facilitate drug passage to the brain, brain shuttles utilize endogenous transport pathways, such as receptor-mediated and adsorptive-mediated transcytosis. In vitro BBB models provide a controlled environment to evaluate the passage of brain shuttles across the BBB. Here, we present the cellular and methodological basis for selecting an appropriate model type for any shuttle study, with relevant barrier tightness and cellular composition. We explain how to apply rigorous experimental controls to assess transport efficiency, receptor specificity, cytotoxicity, and barrier integrity, which helps to identify specific transport phenomena, and exclude artefacts. Copyright © 2026. Published by Elsevier Inc.”
A new study breaks down how in vitro BBB models are unlocking the next phase of brain shuttle peptide research. Instead of guessing what happens in live animals, researchers can now use lab-grown BBB systems to put shuttles to the test. That means more control, better data, and less noise. The models can mimic barrier tightness, cellular makeup, and even the specific transport routes—receptor-mediated or adsorptive-mediated transcytosis—that shuttles use.
Key takeaway: You don’t need to fly blind anymore. If you’re developing or testing a brain shuttle peptide, these in vitro models let you:
Measure how efficiently your peptide crosses the barrier
Confirm it’s using the intended receptor pathway
Check for unwanted cytotoxicity or barrier disruption
Eliminate false positives from leaky models
Why does this matter? Streamlined models accelerate screening and optimization, so you can iterate on your design before moving to animal studies. That saves time, money, and headaches. It’s a leap forward for anyone working on neurotherapeutic peptide delivery.
For anyone deep in the peptide game, this is the kind of tool that can change your workflow. Check out the peptide research index if you want to dig deeper or find the latest advances in BBB-targeting peptides. The more we understand and control these barriers, the more options we unlock for brain research.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.